Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jocelyn Yelle

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Therapeutic Targets|January 24, 2003
Targeting HIV-1 integraseKhampoune Sayasith, Gilles Sauvé, Jocelyn Yelle
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studiesAbderrahim Bouzide, Gilles Sauvé, Jocelyn Yelle
Bioorganic & Medicinal Chemistry Letters|September 25, 2003
1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitorsAbderrahim Bouzide, Gilles Sauvé, Guy Sévigny, et al.
AAPS Pharmsci|July 10, 2002
Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?Carole Lavigne, Jocelyn Yelle, Gilles Sauve, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacerBrent R Stranix, Gilles Sauvé, Abderrahim Bouzide, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureasBrent R Stranix, Gilles Sauvé, Abderrahim Bouzide, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2006
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acidsBrent R Stranix, Jean-François Lavallée, Guy Sévigny, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1Serge Dandache, Guy Sévigny, Jocelyn Yelle, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Therapeutic Targets|January 24, 2003
Targeting HIV-1 integraseKhampoune Sayasith, Gilles Sauvé, Jocelyn Yelle
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studiesAbderrahim Bouzide, Gilles Sauvé, Jocelyn Yelle
Bioorganic & Medicinal Chemistry Letters|September 25, 2003
1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitorsAbderrahim Bouzide, Gilles Sauvé, Guy Sévigny, et al.
AAPS Pharmsci|July 10, 2002
Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?Carole Lavigne, Jocelyn Yelle, Gilles Sauve, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacerBrent R Stranix, Gilles Sauvé, Abderrahim Bouzide, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureasBrent R Stranix, Gilles Sauvé, Abderrahim Bouzide, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2006
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acidsBrent R Stranix, Jean-François Lavallée, Guy Sévigny, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1Serge Dandache, Guy Sévigny, Jocelyn Yelle, et al.
Pageof 1